Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $18.00 at Leerink Partners

Lexeo Therapeutics (NASDAQ:LXEO - Free Report) had its target price trimmed by Leerink Partners from $19.00 to $18.00 in a research report report published on Monday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Separately, Royal Bank of Canada reiterated an "outperform" rating and issued a $24.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $22.80.

Lexeo Therapeutics Stock Up 0.4 %

NASDAQ LXEO traded up $0.02 during mid-day trading on Monday, reaching $4.13. The stock had a trading volume of 83,075 shares, compared to its average volume of 343,614. The company has a fifty day moving average price of $4.07 and a 200 day moving average price of $6.63. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.50. The stock has a market cap of $136.40 million, a PE ratio of -1.32 and a beta of 3.85.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09. On average, research analysts expect that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Remove Ads

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP grew its position in Lexeo Therapeutics by 48.3% during the fourth quarter. Wellington Management Group LLP now owns 76,981 shares of the company's stock valued at $507,000 after buying an additional 25,089 shares during the period. Woodline Partners LP grew its position in shares of Lexeo Therapeutics by 0.8% during the 4th quarter. Woodline Partners LP now owns 858,691 shares of the company's stock valued at $5,650,000 after acquiring an additional 6,730 shares during the period. Vestal Point Capital LP raised its holdings in Lexeo Therapeutics by 41.2% in the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company's stock worth $7,896,000 after purchasing an additional 350,000 shares during the period. Point72 Asset Management L.P. lifted its position in Lexeo Therapeutics by 102.5% during the fourth quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company's stock valued at $4,937,000 after purchasing an additional 379,828 shares in the last quarter. Finally, Millennium Management LLC increased its position in Lexeo Therapeutics by 282.5% in the fourth quarter. Millennium Management LLC now owns 141,951 shares of the company's stock worth $934,000 after buying an additional 104,837 shares in the last quarter. Hedge funds and other institutional investors own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.